Article Hero

Moderna continues to be on an upward trend

Miguel A. Rodriguez
Miguel A. Rodriguez
14 September 2020
The idea of a vaccine is getting closer and closer to becoming a reality.

The week debuted with good news for and from Moderna.  

The company announced that it secured a funding of $472 million from the US government to further develop a COVID-19 vaccine. The money will be used to start a late-stage clinical trial, with an extended Phase III study of the vaccine.

It is the second funding that Moderna receives from the government. Back in April, it got $483 million from the Biomedical Advanced Research and Development Authority to continue its research amid positive data collected from the Phase I trial.

The company is moving on with its Phase III trial, which will consist of up to 30,000 people. It will be a placebo-controlled trial, conducted with the National Institute of Allergy and Infectious Diseases. The endgame is the prevention of symptomatic COVID-19, while the virus contraction and preventing the severe forms which require hospitalization will be resolved along the way. 

Today the share price gained more than 11%. Pushed by the fact that it is the front-runner for developing a viable COVID-19 vaccine, the stock price increased more than 270% this year, while USA500 slid 0.4%. 

Read more about the pharmaceutical companies here! Register and check out our Corona Blend!







Miguel A. Rodriguez
Miguel A. Rodriguez

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.